CoChat

Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the effects of the anti-TNF-α monoclonal antibody golimumab, administered by s.c. injection or i.v. infusion, on markers of inflammation in patients with RA. METHODS: In this phase 1, open-label study, patients with active RA were randomized to receive s.c. golimumab 100 mg at baseline and every 4 weeks through week 20 (n = 33; group 1) or i.v. golimumab 2 mg/kg at baseline and week 12 (n = 16; group 2). Serum levels of CRP, IL-6, serum amyloid A (SAA), TNF receptor II (TNFRII), MMP-3, hyaluronic acid, haptoglobin, ferritin and haemoglobin and serum/urine hepcidin were measured at various time points. Associations between the biomarkers were assessed with Spearman's correlations. RESULTS: In both groups 1 and 2, decreases in mean serum levels of CRP, IL-6, SAA, TNFRII, MMP-3, haptoglobin, ferritin and hepcidin, and mean urine levels of hepcidin occurred within 1 week and were sustained through week 8. Decreases in concentrations of serum CRP, IL-6, SAA, MMP-3, hepcidin, ferritin and haptoglobin and urine hepcidin were maintained through week 24 in group 1, but began to reverse after week 8 in group 2. Among all patients, decreases in serum hepcidin correlated significantly with decreases in serum CRP and ferritin. CONCLUSION: Decreases in serum and urine concentrations of markers of inflammation occurred as early as 24 h after treatment with golimumab, and most of these improvements were sustained through week 24 in group 1.

Overview

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kes381

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. van Riel, 2000, EULAR handbook of clinical assessments in rheumatoid arthritis

Cited by

See all 40

Metadata

Authors
Doyle, M. K., Rahman, M. U., Frederick, B., Birbara, C. A., de Vries, D., Toedter, G., Wu, X., Chen, D., Ranganath, V. K., Westerman, M. E., & Furst, D. E.
Affiliations
  • Janssen Research & Development (United States) (US)
  • University of California, Los Angeles (US)
Venue
Rheumatology
Published
2013-02-14
Volume
52
Issue
7
Pages
1214-1219
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
OpenAlex
W2120116963
Cited by
40
References
25
Citations by year
2024: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 8 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 1
FWCI
3.83
Type
journal article
Language
en
Open access
closed
Locations
  • Lara D. Veeken (publishedVersion)
  • PubMed (publishedVersion)
Funders
Genentech
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
golimumab, rheumatoid arthritis, anti-TNF monoclonal antibody, subcutaneous administration, intravenous infusion, inflammatory markers, C-reactive protein, interleukin-6, serum amyloid A, TNF receptor 2, matrix metalloproteinase-3, hepcidin, ferritin, haptoglobin, hyaluronic acid, treatment response
MeSH terms
Adult, Antibodies, Monoclonal, Arthritis, Rheumatoid, C-Reactive Protein, Ferritins, Humans, Inflammation, Injections, Intravenous, Injections, Subcutaneous, Tumor Necrosis Factor-alpha, Biomarkers, Interleukin-6, Treatment Outcome, Matrix Metalloproteinase 3, Antimicrobial Cationic Peptides, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. https://app.cochat.ai/papers/10.1093/rheumatology/kes381
The paper
Doyle, M. K., Rahman, M. U., Frederick, B., Birbara, C. A., de Vries, D., Toedter, G., Wu, X., Chen, D., Ranganath, V. K., Westerman, M. E., & Furst, D. E. (2013). Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology. https://doi.org/10.1093/rheumatology/kes381

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.